Lineage Cell Therapeutics, Inc. Finite-lived Intangible Assets Acquired
Lineage Cell Therapeutics, Inc. (LCTX) reported Finite-lived Intangible Assets Acquired of $46.50 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Notes › Intangible Assets › Goodwill and Other
us-gaap:FinitelivedIntangibleAssetsAcquired1 · last filed 2023-08-10
- Lineage Cell Therapeutics, Inc. finite-lived intangible assets acquired for the quarter ending 2023-06-30 was $0.00.
- Lineage Cell Therapeutics, Inc. finite-lived intangible assets acquired for the quarter ending 2023-03-31 was $46.50M, a 0.00% change year-over-year.
- Lineage Cell Therapeutics, Inc. finite-lived intangible assets acquired for the quarter ending 2022-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. finite-lived intangible assets acquired for the quarter ending 2022-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. finite-lived intangible assets acquired for fiscal 2022 was $46.50M, a 0.00% change from fiscal 2021.
- Lineage Cell Therapeutics, Inc. finite-lived intangible assets acquired for fiscal 2021 was $46.50M.
| Period end | Finite-lived Intangible Assets Acquired 3 month | Finite-lived Intangible Assets Acquired 6 month | Finite-lived Intangible Assets Acquired 9 month | Finite-lived Intangible Assets Acquired 12 month |
|---|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $46.50M 10-Q · filed 2023-08-10 | $46.50M derived: sum of 3 quarters · filed 2023-08-10 | $46.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | $46.50M 10-Q · filed 2023-05-11 | $46.50M derived: sum of 2 quarters · filed 2023-05-11 | $46.50M derived: sum of 3 quarters · filed 2023-05-11 | $46.50M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $46.50M 10-K · filed 2023-03-09 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $46.50M 10-Q · filed 2022-11-10 | $46.50M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $46.50M 10-Q · filed 2022-08-11 | $46.50M derived: sum of 3 quarters · filed 2022-08-11 | $46.50M derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | $46.50M 10-Q · filed 2022-05-12 | $46.50M derived: sum of 2 quarters · filed 2022-05-12 | $46.50M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $46.50M 10-K · filed 2022-03-10 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $46.50M 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | $46.50M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |